59
We congratulate Catherine Arundel and colleagues on the publication of the SWHSI-2 trial1 and commend the authors and collaborators on successfully recruiting 686 patients (1895 screened) into this landmark study—an exemplary achievement under any circumstance, but truly outstanding considering the profound disruptions caused by the COVID-19 pandemic to National Health Service (NHS) acute care services. The authors’ effort is a remarkable demonstration of the UK’s continued commitment to advancing evidence-based medicine, and it stands as a testament to the resilience of the UK’s clinical research infrastructure.
